Phase III
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants with Lichen Sclerosus
- Study IRB#:2000041937
- Last Updated:10/14/2026
This is an interventional, multicenter, multinational Phase 3 trial which comprises a 12-week, double-blinded, vehicle-controlled initial treatment period, followed by a 40-week, double-blinded, vehicle-controlled continuation treatment period. This trial will evaluate efficacy, safety, and Health-related Quality of Life (HRQoL) of delgocitinib cream 8 mg/g and 20 mg/g in adult participants with anogenital lichen sclerosus (LS).
- Age18 years and older
- GenderFemale only
Contact Us
For more information about this study, including how to volunteer, contact:
Rehema Mtawali
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877-978-8343 for more information.
Eligibility Criteria
- Age 18 years or older at the time of signing informed consent.
- Female participants (assigned sex female at birth, and has not had any gender affirming medical procedures to their genital area) with Lichen Sclerosis in the anogenital area.
- Disease severity graded as mild to severe at screening and baseline.
